John Fetterman gives us a chance to banish eugenic ideas of fitness
By Jaipreet Virdi,
The Washington Post
| 11. 04. 2022
Photo by visuals on Unsplash
Democrat John Fetterman’s performance in Pennsylvania’s lone Senate debate provoked intense discussions about his fitness for office while recovering from a stroke. Fetterman’s verbal stumbles and pauses intensified Republican accusations that his health is too frail to withstand the job of a senator, even as doctors and disability advocates pushed back on these charges. But while some saw Fetterman’s halting speech and need for closed captioning as evidence of cognitive impairment, the conversation surrounding his fitness is premised on bias and ableism. The polished, articulate and groomed image we associate with the ideal politician means that anyone who does not meet this ideal is considered subpar — and hence “unfit.” But that understanding of what makes someone capable of holding office is actually rooted in eugenics.
In 1883, British polymath Sir Francis Galton first developed eugenics as a science for improving the inborn qualities of the human race. Eugenics swept into American society around the turn of the 20th century as a Progressive solution for addressing widespread problems caused by groups deemed “socially inadequate.” As...
Related Articles
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...
By Ben Fidler and Ned Pagliarulo, Biopharma Dive | 07.21.2025
One month ago, a 51-year-old man treated in a clinical trial with an experimental gene therapy became dangerously sick. The developer of that treatment, Sarepta Therapeutics, informed the Food and Drug Administration his case could be life-threatening.
The man died...
By Pat Duggins, Alabama Public Radio | 06.27.2025
PAT DUGGINS-- If I were to say, ‘man, have you seen the price of eggs these days?’ You're probably thinking, Oh, he's talking about inflation and the price of groceries and how it became an issue in the presidential race...